A small molecule inhibitor to plasminogen activator inhibitor 1 inhibits macrophage migration.

Methyltetrahydrofolate Reductase C677T Mutation and 4G/5G Plasminogen Activator Inhibitor-1 Polymorphism in a Child with Deep Vein Thrombosis

Serum Level of Plasminogen Activator Inhibitor Type-1 in Addicted Patients ‎with Coronary Artery Disease

Background: Plasminogen activator inhibitor-1 (PAI-1) is a glycoprotein with inhibitory effects on the formation of plasmin from plasminogen by plasminogen activator. Thus, it prevents clot lysis in vessel walls. Several evidences prove the relationship between coronary artery disease and response to fibrinolytic therapy in patients with myocardial infarction with PAI-1 level. Opium addiction i...

The Effects of Regular Aerobic Exercise on the serum levels of Plasminogen Activator Inhibitor-1 and Adiponectin in Obese Girls

Background: The modification of the adipokine levels can be important for the long-term prevention of systemic inflammation related to obesity in children. Objective: The current study aimed to investigate the effects of regular aerobic exercise on the serum levels of plasminogen Activator inhibitor-1(PAI-1) and Adiponectin in obese girls. Methods: This semi experimental research, 14 obese gi...

Plasminogen Activator Inhibitor-1 4G/5G Polymorphism Contributes to Osteonecrosis of the Femoral Head Susceptibility: Evidence from a Systematic Review and Meta-analysis

Background: The Plasminogen Activator Inhibitor-1 gene 4G/5G (PAI-1 4G/5G) polymorphism has been suggestedto be associated with osteonecrosis of the femoral head (ONFH) susceptibility; however, the results are conflicting andinconclusive. We have carried out a comprehensive meta-analysis to derive a more precise estimation of the association.Methods: A comprehensive search in PubMed, EMBASE, Go...

Mechanistic characterization and crystal structure of a small molecule inactivator bound to plasminogen activator inhibitor-1.

Plasminogen activator inhibitor type-1 (PAI-1) is a member of the serine protease inhibitor (serpin) family. Excessive PAI-1 activity is associated with human disease, making it an attractive pharmaceutical target. However, like other serpins, PAI-1 has a labile structure, making it a difficult target for the development of small molecule inhibitors, and to date, there are no US Food and Drug A...